Close
Advanced Search

Abstract

Aims

Filamin-A (FLNA) was identified as the first gene of non-syndromic mitral valve dystrophy (FLNA-MVD). We aimed to assess the phenotype of FLNA-MVD and its impact on prognosis.

Methods and results

We investigated the disease in 246 subjects (72 mutated) from four FLNA-MVD families harbouring three different FLNA mutations. Phenotype was characterized by a comprehensive echocardiography focusing on mitral valve apparatus in comparison with control relatives. In this X-linked disease valves lesions were severe in men and moderate in women. Most men had classical features of mitral valve prolapse (MVP), but without chordal rupture. By contrast to regular MVP, mitral leaflet motion was clearly restricted in diastole and papillary muscles position was closer to mitral annulus. Valvular abnormalities were similar in the four families, in adults and young patients from early childhood suggestive of a developmental disease. In addition, mitral valve lesions worsened over time as encountered in degenerative conditions. Polyvalvular involvement was frequent in males and non-diagnostic forms frequent in females. Overall survival was moderately impaired in men (P = 0.011). Cardiac surgery rate (mainly valvular) was increased (33.3 ± 9.8 vs. 5.0 ± 4.9%, P < 0.0001; hazard ratio 10.5 [95% confidence interval: 2.9–37.9]) owing mainly to a lifetime increased risk in men (76.8 ± 14.1 vs. 9.1 ± 8.7%, P < 0.0001).

Conclusion

FLNA-MVD is a developmental and degenerative disease with complex phenotypic expression which can influence patient management. FLNA-MVD has unique features with both MVP and paradoxical restricted motion in diastole, sub-valvular mitral apparatus impairment and polyvalvular lesions in males. FLNA-MVD conveys a substantial lifetime risk of valve surgery in men.

graphic
View largeDownload slide
graphic
View largeDownload slide
Mitral valve prolapse, Echocardiography, Genetic, Cardiac surgery, Filamine-A

Introduction

Mitral valve prolapse (MVP) is a common valve disorder which affects 2–3% of the population and is a major cause of valve surgery.1 Non-syndromic MVP, the most common form of the disease, encompasses different phenotypes from Fibro-elastic deficiency to classical Barlow disease.2–5 Familial inheritance of MVP has been largely recognized.1,6,7 Autosomal dominant transmission is the usual inheritance mode2,8 but an X-linked recessive form of mitral valve dystrophy (MVD) has been first encountered.6,9 The recent identification of genetic defects associated with either MVP or MVD allows starting to decipher genotype–phenotype relationship.7,10,11 The X-linked form [Filamin-A (FLNA)-MVD] was associated to a mutation in the FLNA (p.Pro637Gln, FLNA-P637Q) gene (OMIM 314400).7 Three other FLNA defects were subsequently identified.7,12,13 Filamin-A is a widely expressed hub protein involved in cardiac development, particularly in leaflets during fetal valve morphogenesis. Filamin-A molecular and cellular alterations leading to MVD impair the organization of cell actin network, cell spreading and migration capacities, the interaction with small-GTPase and therefore the response to mechanical stress.14

Due to the absence of gene identification until recently, the overall spectrum of either MVP or MVD including atypical features has been poorly characterized. In particular, and despite first attempts,15 phenotype and outcome characteristics of FLNA-MVD, which presents unique features compared with Barlow disease and Fibro-elastic deficiency, remained to be explored. Hence, this FLNA-MVD study was designed (i) to assess the genotype-phenotype relationship and (ii) to examine the outcome of patients.

Methods

The present study is based on a retrospective series of 246 subjects, from four FLNA-MVD families harbouring three different FLNA missense mutations, in whom we ascertained the FLNA genetic status. Echocardiography was carried out in 162 relatives. The study complies with the Declaration of Helsinki, the French guidelines for genetic research and was approved by local ethic committees. Written informed consent was obtained.

Phenotypic study

Patients and relatives from the four families (Families 1, 2, 3, and 4) were enrolled (see Supplementary material online, FigureS1). The genotype–phenotype FLNA study comprised all relatives of the four families in whom we obtained an echocardiography. Echocardiography was available for 162 subjects including 65 with FLNA mutations (90% of known mutated patients). Subjects not carrying the mutation served as controls (n = 97). A comprehensive clinical examination was carried out.

In Family 1, of French origin, the phenotypic study comprised 151 relatives with or without FLNA-P637Q mutation. Family 2, presenting a de novo FLNA-H743P mutation, comprised three relatives. In Family 3 (G288R mutation), of European origin, which was previously published,12 echocardiograms were available for two male children. Finally, echocardiography was carried out in six patients in Family 4 (G288R mutation) previously published.13 In this family, histological analysis of one mitral leaflet segment obtained during MV repair was available. Mutations (Figure 1) are localized in the N-terminal part of the protein (NP_001104026).7

Figure 1
 (A) Filamin-A protein with the C-terminal and N-terminal parts, and the three missense mutations localization, (B) microphotograph of a mitral leaflet piece (FLNA-G288R, Family 4, resection during mitral valve repair) showing a nodular thickened valve with myxomatous degeneration (colloidal iron, original magnification × 20), (C) typical aspect in echocardiography of the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in a P637Q patient in the parasternal long-axis view, (D) with moderate MR in the apical view.
View largeDownload slide

 (A) Filamin-A protein with the C-terminal and N-terminal parts, and the three missense mutations localization, (B) microphotograph of a mitral leaflet piece (FLNA-G288R, Family 4, resection during mitral valve repair) showing a nodular thickened valve with myxomatous degeneration (colloidal iron, original magnification × 20), (C) typical aspect in echocardiography of the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in a P637Q patient in the parasternal long-axis view, (D) with moderate MR in the apical view.

Figure 1
 (A) Filamin-A protein with the C-terminal and N-terminal parts, and the three missense mutations localization, (B) microphotograph of a mitral leaflet piece (FLNA-G288R, Family 4, resection during mitral valve repair) showing a nodular thickened valve with myxomatous degeneration (colloidal iron, original magnification × 20), (C) typical aspect in echocardiography of the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in a P637Q patient in the parasternal long-axis view, (D) with moderate MR in the apical view.
View largeDownload slide

 (A) Filamin-A protein with the C-terminal and N-terminal parts, and the three missense mutations localization, (B) microphotograph of a mitral leaflet piece (FLNA-G288R, Family 4, resection during mitral valve repair) showing a nodular thickened valve with myxomatous degeneration (colloidal iron, original magnification × 20), (C) typical aspect in echocardiography of the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in a P637Q patient in the parasternal long-axis view, (D) with moderate MR in the apical view.

Echocardiography

Echocardiograms were carried out according to the current recommendations16–18 using a commercially available ultrasound system (Vivid, GE Medical Systems, Milwaukee, WI, USA in most cases). Mitral valve (MV) apparatus was comprehensively assessed (see Supplementary Material online).

Follow-up

The outcome study was conducted from birth to 2016 and comprised the 246 relatives (72 mutated, 174 non-mutated). Total follow-up was 42 ± 22 years, ranging from 5 months (birth in 2016) to 87 years. The end points were overall survival and cardiac surgery rates in the whole population and after stratification according to gender.

Statistical analysis

Results are expressed as mean ± standard deviation, median (25–75th percentiles) or number (percentage). Comparisons between groups were performed with Student’s t-tests, or χ2 tests, as appropriate. We analysed the association of mutation status with all the trait while accounting for familial correlation using variance decomposition. We used SOLAR software which simultaneously estimated the heritability of the trait, based on the phenotype and the kinship coefficient and the effect of the mutation status. The significance of the mutation effect was evaluated through a likelihood ratio test. Mitral valve measurement associations with age were tested with linear and non-linear regression and the best fit was retained. Overall survival and cardiac surgery rates were calculated by the Kaplan–Meier method and were compared with the Log-rank test. The association of FLNA mutation to end points used the Cox proportional hazards method. A two-tailed P-value ≤ 0.05 was considered significant. Statistical analyses were performed with SPSS software version 13 (SPSS, Chicago, IL, USA) and R version 3.3.2.

Results

Baseline characteristics of the 162 relatives enrolled in the phenotypic study are shown in Table 1. Clinical examination found only benign joint hypermobility syndrome and narrow palate in some individuals. No patient had pectus excavatum, severe scoliosis or severe myopia (see Supplementary Material online). Neurological status was normal in all patients, and brain magnetic resonance imaging carried out in severe FLNA-MVD (n = 8) were normal ruling out periventricular heterotopia (data not shown).

Table 1

Baseline characteristics of FLNA-MVD patients (FLNA+) and control relatives (FLNA−) from four families in the genotype–phenotype study at the time of echocardiography

 FLNA +  (n = 65) FLNA– (n = 97) P-value 
Age, years 35 ± 22 37 ± 20 0.55 
Age ≥16 years, n (%) 49 (75) 82 (85) 0.21 
Male, n (%) 25 (38) 57 (59) 0.02 
Heart rate, beat/min 76 ± 16 71 ± 13 0.03 
Systolic blood pressure, mmHg 122 ± 17 128 ± 17 0.03 
Hypertension, n (%) 5 (7.7) 10 (10.3) 0.77 
Diabetes, n (%) 3 (4.6) 1 (1) 0.36 
Dyslipidaemia, n (%) 8 (12.3) 7 (7.2) 0.41 
Tobacco, n (%) 14 (21.5) 10 (10.3) 0.08 
Filamin-A mutation 
 P637Q 55 — — 
 H743P 2 — — 
 G288R 8 — — 
 FLNA +  (n = 65) FLNA– (n = 97) P-value 
Age, years 35 ± 22 37 ± 20 0.55 
Age ≥16 years, n (%) 49 (75) 82 (85) 0.21 
Male, n (%) 25 (38) 57 (59) 0.02 
Heart rate, beat/min 76 ± 16 71 ± 13 0.03 
Systolic blood pressure, mmHg 122 ± 17 128 ± 17 0.03 
Hypertension, n (%) 5 (7.7) 10 (10.3) 0.77 
Diabetes, n (%) 3 (4.6) 1 (1) 0.36 
Dyslipidaemia, n (%) 8 (12.3) 7 (7.2) 0.41 
Tobacco, n (%) 14 (21.5) 10 (10.3) 0.08 
Filamin-A mutation 
 P637Q 55 — — 
 H743P 2 — — 
 G288R 8 — — 
Table 1

Baseline characteristics of FLNA-MVD patients (FLNA+) and control relatives (FLNA−) from four families in the genotype–phenotype study at the time of echocardiography

 FLNA +  (n = 65) FLNA– (n = 97) P-value 
Age, years 35 ± 22 37 ± 20 0.55 
Age ≥16 years, n (%) 49 (75) 82 (85) 0.21 
Male, n (%) 25 (38) 57 (59) 0.02 
Heart rate, beat/min 76 ± 16 71 ± 13 0.03 
Systolic blood pressure, mmHg 122 ± 17 128 ± 17 0.03 
Hypertension, n (%) 5 (7.7) 10 (10.3) 0.77 
Diabetes, n (%) 3 (4.6) 1 (1) 0.36 
Dyslipidaemia, n (%) 8 (12.3) 7 (7.2) 0.41 
Tobacco, n (%) 14 (21.5) 10 (10.3) 0.08 
Filamin-A mutation 
 P637Q 55 — — 
 H743P 2 — — 
 G288R 8 — — 
 FLNA +  (n = 65) FLNA– (n = 97) P-value 
Age, years 35 ± 22 37 ± 20 0.55 
Age ≥16 years, n (%) 49 (75) 82 (85) 0.21 
Male, n (%) 25 (38) 57 (59) 0.02 
Heart rate, beat/min 76 ± 16 71 ± 13 0.03 
Systolic blood pressure, mmHg 122 ± 17 128 ± 17 0.03 
Hypertension, n (%) 5 (7.7) 10 (10.3) 0.77 
Diabetes, n (%) 3 (4.6) 1 (1) 0.36 
Dyslipidaemia, n (%) 8 (12.3) 7 (7.2) 0.41 
Tobacco, n (%) 14 (21.5) 10 (10.3) 0.08 
Filamin-A mutation 
 P637Q 55 — — 
 H743P 2 — — 
 G288R 8 — — 

Mitral valve in FLNA-MVD patients

The main quantitative characteristics of MV apparatus, restricted to adult patients for ensuring a reliable comparative analysis, are shown in Table 2. Figure 1 shows a typical but moderate aspect of FLNA-MVD with mitral regurgitation (MR). Figure 2 displays a schematic of MV apparatus in controls (A) and FLNA patients (B and C). Men had a severe phenotype characterized by elongation of anterior (AL) and posterior (PL) leaflets. Both leaflets were thickened, billowing or prolapsing, redundant and frequently curled at their tip. By contrast, MV lesions were mild to moderate in women as expected in an X-linked disease. Only one woman (FLNA-H743P) had a severe phenotype owing to an extremely skewed X-chromosome inactivation (see Supplementary Material online). Mitral valve prolapse was found in 26 adult patients (53%), was more frequent in men (70%) compared with women (44%), and involved only the AL (10%), the PL (22%), or both leaflets (20%). In addition, minimal systolic displacement, a prodromal form of MVP, was found in six adults (12%), five women (16%), and one man (6%). The MV apparatus was similar to adult one in younger patients from early childhood. Histological analysis of a mitral leaflet segment demonstrated myxomatous degeneration (Figure 1).

Table 2

Mitral valve apparatus in FLNA-MVD men and women (≥16 years old) compared with controls

 FLNA + men FLNA − men P-value FLNA + women FLNA − women P-value 
Mitral annulus diameter, mm/m2 21 ± 2 17 ± 2 0.12 19 ± 2** 18 ± 2 0.9 
Mitral orifice area, cm2/m2 1.5 ± 0.4 1.8 ± 0.4 0.03 1.6 ± 0.3 1.7 ± 0.5 0.37 
Leaflet length       
 Anterior leaflet length, mm/m2 13.5 ± 2.1 11.5 ± 1.4 0.0004 12.7 ± 2.0 12.0 ± 1.4 0.81 
 Posterior leaflet length, mm/m2 8.8 ± 1.5 6.2 ± 1.3 <0.0001 6.6 ± 1.1* 5.9 ± 1.2 0.07 
 Anterior/posterior leaflet length ratio 1.5 ± 0.3 1.9 ± 0.3 0.0002 1.9 ± 0.4 2.1 ± 0.7 0.17 
Leaflet thickness       
 Tip anterior leaflet thickness, mm/m2 2.1 ± 0.6 1.1 ± 0.2 <0.0001 1.5 ± 0.4** 1.2 ± 0.3 0.08 
 Tip posterior leaflet thickness, mm/m2 2.0 ± 0.5 1.1 ± 0.3 <0.0001 1.4 ± 0.4* 1.1 ± 0.3 0.001 
Leaflet position to annulus line       
 Anterior leaflet position, mm/m2 −0.8 ± 1.5 1.9 ± 0.7 0.01 0.5 ± 1.5** 1.6 ± 0.9 0.16 
 Posterior leaflet position, mm/m2 −0.9 ± 1.5 1.8 ± 1.1 <0.0001 −0.1 ± 1.9 1.7 ± 0.7 0.008 
 Anterior leaflet prolapse, % 9 (53) 0 — 6 (19) 0 — 
 Posterior leaflet prolapse, % 11 (65) 0 — 9 (28) 0 — 
Subvalvular apparatus       
 Anterior chordal length, mm/m2 11.5 ± 2.2 11.8 ± 1.6 0.55 10.2 ± 2.2** 12.1 ± 2.0 0.02 
 Posterior chordal length, mm/m2 10.8 ± 2.2 12.4 ± 2.1 0.10 10.6 ± 1.9 12.2 ± 2.2 0.009 
 Anterior PM tip/LV length, % 27 ± 4% 32 ± 4% 0.0002 27 ± 3% 31 ± 5% 0.02 
 Posterior PM tip/LV length, % 25 ± 4% 33 ± 5% <0.0001 28 ± 4% 32 ± 4% 0.0009 
 FLNA + men FLNA − men P-value FLNA + women FLNA − women P-value 
Mitral annulus diameter, mm/m2 21 ± 2 17 ± 2 0.12 19 ± 2** 18 ± 2 0.9 
Mitral orifice area, cm2/m2 1.5 ± 0.4 1.8 ± 0.4 0.03 1.6 ± 0.3 1.7 ± 0.5 0.37 
Leaflet length       
 Anterior leaflet length, mm/m2 13.5 ± 2.1 11.5 ± 1.4 0.0004 12.7 ± 2.0 12.0 ± 1.4 0.81 
 Posterior leaflet length, mm/m2 8.8 ± 1.5 6.2 ± 1.3 <0.0001 6.6 ± 1.1* 5.9 ± 1.2 0.07 
 Anterior/posterior leaflet length ratio 1.5 ± 0.3 1.9 ± 0.3 0.0002 1.9 ± 0.4 2.1 ± 0.7 0.17 
Leaflet thickness       
 Tip anterior leaflet thickness, mm/m2 2.1 ± 0.6 1.1 ± 0.2 <0.0001 1.5 ± 0.4** 1.2 ± 0.3 0.08 
 Tip posterior leaflet thickness, mm/m2 2.0 ± 0.5 1.1 ± 0.3 <0.0001 1.4 ± 0.4* 1.1 ± 0.3 0.001 
Leaflet position to annulus line       
 Anterior leaflet position, mm/m2 −0.8 ± 1.5 1.9 ± 0.7 0.01 0.5 ± 1.5** 1.6 ± 0.9 0.16 
 Posterior leaflet position, mm/m2 −0.9 ± 1.5 1.8 ± 1.1 <0.0001 −0.1 ± 1.9 1.7 ± 0.7 0.008 
 Anterior leaflet prolapse, % 9 (53) 0 — 6 (19) 0 — 
 Posterior leaflet prolapse, % 11 (65) 0 — 9 (28) 0 — 
Subvalvular apparatus       
 Anterior chordal length, mm/m2 11.5 ± 2.2 11.8 ± 1.6 0.55 10.2 ± 2.2** 12.1 ± 2.0 0.02 
 Posterior chordal length, mm/m2 10.8 ± 2.2 12.4 ± 2.1 0.10 10.6 ± 1.9 12.2 ± 2.2 0.009 
 Anterior PM tip/LV length, % 27 ± 4% 32 ± 4% 0.0002 27 ± 3% 31 ± 5% 0.02 
 Posterior PM tip/LV length, % 25 ± 4% 33 ± 5% <0.0001 28 ± 4% 32 ± 4% 0.0009 

Data are indexed to body surface area.

LV, left ventricle; PM, papillary muscle.

*

P < 0.0001,

**

P < 0.05, for comparison between men and women.

Table 2

Mitral valve apparatus in FLNA-MVD men and women (≥16 years old) compared with controls

 FLNA + men FLNA − men P-value FLNA + women FLNA − women P-value 
Mitral annulus diameter, mm/m2 21 ± 2 17 ± 2 0.12 19 ± 2** 18 ± 2 0.9 
Mitral orifice area, cm2/m2 1.5 ± 0.4 1.8 ± 0.4 0.03 1.6 ± 0.3 1.7 ± 0.5 0.37 
Leaflet length       
 Anterior leaflet length, mm/m2 13.5 ± 2.1 11.5 ± 1.4 0.0004 12.7 ± 2.0 12.0 ± 1.4 0.81 
 Posterior leaflet length, mm/m2 8.8 ± 1.5 6.2 ± 1.3 <0.0001 6.6 ± 1.1* 5.9 ± 1.2 0.07 
 Anterior/posterior leaflet length ratio 1.5 ± 0.3 1.9 ± 0.3 0.0002 1.9 ± 0.4 2.1 ± 0.7 0.17 
Leaflet thickness       
 Tip anterior leaflet thickness, mm/m2 2.1 ± 0.6 1.1 ± 0.2 <0.0001 1.5 ± 0.4** 1.2 ± 0.3 0.08 
 Tip posterior leaflet thickness, mm/m2 2.0 ± 0.5 1.1 ± 0.3 <0.0001 1.4 ± 0.4* 1.1 ± 0.3 0.001 
Leaflet position to annulus line       
 Anterior leaflet position, mm/m2 −0.8 ± 1.5 1.9 ± 0.7 0.01 0.5 ± 1.5** 1.6 ± 0.9 0.16 
 Posterior leaflet position, mm/m2 −0.9 ± 1.5 1.8 ± 1.1 <0.0001 −0.1 ± 1.9 1.7 ± 0.7 0.008 
 Anterior leaflet prolapse, % 9 (53) 0 — 6 (19) 0 — 
 Posterior leaflet prolapse, % 11 (65) 0 — 9 (28) 0 — 
Subvalvular apparatus       
 Anterior chordal length, mm/m2 11.5 ± 2.2 11.8 ± 1.6 0.55 10.2 ± 2.2** 12.1 ± 2.0 0.02 
 Posterior chordal length, mm/m2 10.8 ± 2.2 12.4 ± 2.1 0.10 10.6 ± 1.9 12.2 ± 2.2 0.009 
 Anterior PM tip/LV length, % 27 ± 4% 32 ± 4% 0.0002 27 ± 3% 31 ± 5% 0.02 
 Posterior PM tip/LV length, % 25 ± 4% 33 ± 5% <0.0001 28 ± 4% 32 ± 4% 0.0009 
 FLNA + men FLNA − men P-value FLNA + women FLNA − women P-value 
Mitral annulus diameter, mm/m2 21 ± 2 17 ± 2 0.12 19 ± 2** 18 ± 2 0.9 
Mitral orifice area, cm2/m2 1.5 ± 0.4 1.8 ± 0.4 0.03 1.6 ± 0.3 1.7 ± 0.5 0.37 
Leaflet length       
 Anterior leaflet length, mm/m2 13.5 ± 2.1 11.5 ± 1.4 0.0004 12.7 ± 2.0 12.0 ± 1.4 0.81 
 Posterior leaflet length, mm/m2 8.8 ± 1.5 6.2 ± 1.3 <0.0001 6.6 ± 1.1* 5.9 ± 1.2 0.07 
 Anterior/posterior leaflet length ratio 1.5 ± 0.3 1.9 ± 0.3 0.0002 1.9 ± 0.4 2.1 ± 0.7 0.17 
Leaflet thickness       
 Tip anterior leaflet thickness, mm/m2 2.1 ± 0.6 1.1 ± 0.2 <0.0001 1.5 ± 0.4** 1.2 ± 0.3 0.08 
 Tip posterior leaflet thickness, mm/m2 2.0 ± 0.5 1.1 ± 0.3 <0.0001 1.4 ± 0.4* 1.1 ± 0.3 0.001 
Leaflet position to annulus line       
 Anterior leaflet position, mm/m2 −0.8 ± 1.5 1.9 ± 0.7 0.01 0.5 ± 1.5** 1.6 ± 0.9 0.16 
 Posterior leaflet position, mm/m2 −0.9 ± 1.5 1.8 ± 1.1 <0.0001 −0.1 ± 1.9 1.7 ± 0.7 0.008 
 Anterior leaflet prolapse, % 9 (53) 0 — 6 (19) 0 — 
 Posterior leaflet prolapse, % 11 (65) 0 — 9 (28) 0 — 
Subvalvular apparatus       
 Anterior chordal length, mm/m2 11.5 ± 2.2 11.8 ± 1.6 0.55 10.2 ± 2.2** 12.1 ± 2.0 0.02 
 Posterior chordal length, mm/m2 10.8 ± 2.2 12.4 ± 2.1 0.10 10.6 ± 1.9 12.2 ± 2.2 0.009 
 Anterior PM tip/LV length, % 27 ± 4% 32 ± 4% 0.0002 27 ± 3% 31 ± 5% 0.02 
 Posterior PM tip/LV length, % 25 ± 4% 33 ± 5% <0.0001 28 ± 4% 32 ± 4% 0.0009 

Data are indexed to body surface area.

LV, left ventricle; PM, papillary muscle.

*

P < 0.0001,

**

P < 0.05, for comparison between men and women.

Figure 2
Schematic of MV apparatus morphology averaged in systole (top) and diastole (bottom) (A) in adult controls, (B) in FLNA-MVD (FLNA+) men and (C) in FLNA-MVD women. In men (B) mitral annulus is 25% larger, mitral leaflets are thickened, redundant, elongated, and prolapsed in systole (top). In addition the distance between papillary muscles tip and mitral annulus line (symbolized by the double black arrow) is reduced by 20%. In diastole (bottom), mitral leaflets motion is limited with a doming aspect. In women (C) MV apparatus changes are moderate. PM, papillary muscle; FLNA, Filamin-A; MVD, mitral valve dystrophy.
View largeDownload slide

Schematic of MV apparatus morphology averaged in systole (top) and diastole (bottom) (A) in adult controls, (B) in FLNA-MVD (FLNA+) men and (C) in FLNA-MVD women. In men (B) mitral annulus is 25% larger, mitral leaflets are thickened, redundant, elongated, and prolapsed in systole (top). In addition the distance between papillary muscles tip and mitral annulus line (symbolized by the double black arrow) is reduced by 20%. In diastole (bottom), mitral leaflets motion is limited with a doming aspect. In women (C) MV apparatus changes are moderate. PM, papillary muscle; FLNA, Filamin-A; MVD, mitral valve dystrophy.

Figure 2
Schematic of MV apparatus morphology averaged in systole (top) and diastole (bottom) (A) in adult controls, (B) in FLNA-MVD (FLNA+) men and (C) in FLNA-MVD women. In men (B) mitral annulus is 25% larger, mitral leaflets are thickened, redundant, elongated, and prolapsed in systole (top). In addition the distance between papillary muscles tip and mitral annulus line (symbolized by the double black arrow) is reduced by 20%. In diastole (bottom), mitral leaflets motion is limited with a doming aspect. In women (C) MV apparatus changes are moderate. PM, papillary muscle; FLNA, Filamin-A; MVD, mitral valve dystrophy.
View largeDownload slide

Schematic of MV apparatus morphology averaged in systole (top) and diastole (bottom) (A) in adult controls, (B) in FLNA-MVD (FLNA+) men and (C) in FLNA-MVD women. In men (B) mitral annulus is 25% larger, mitral leaflets are thickened, redundant, elongated, and prolapsed in systole (top). In addition the distance between papillary muscles tip and mitral annulus line (symbolized by the double black arrow) is reduced by 20%. In diastole (bottom), mitral leaflets motion is limited with a doming aspect. In women (C) MV apparatus changes are moderate. PM, papillary muscle; FLNA, Filamin-A; MVD, mitral valve dystrophy.

Mitral leaflets restrictive motion in diastole

The phenotype of MV disease associated also an unusual doming aspect or restrictive motion in diastole which predominates on the PL (Figures 1 and 2). This aspect was seen in 84% of patients of both genders and any age, and in the three different FLNA mutations. The PL restrictive motion was even the predominant feature of MV involvement in females mimicking with that regard a discrete rheumatic- or drug-induced lesion. Further, a mild-to-moderate degree of congenital MV stenosis with incomplete opening of one commissure was occasionally observed (see Supplementary material online, FigureS2).

Sub-valvular mitral valve apparatus

Mitral valve chordae were shortened (in women) and papillary muscles (PM) development and position were affected (Table 2). No chordal rupture was diagnosed in our series of patients but chordae were occasionally elongated and a few primary chordae were absent in one FLNA-P637Q man. Abnormal leaflet-like tissue replaced most chordae in one patient. In addition, chordae displayed uncommon ‘web’ morphology in a young patient suggestive of a severe impairment of chordae development. Both PM tips were closer to mitral annulus line as compared with controls. Moreover, PMs were absent or severely underdeveloped in two patients with P637Q and G288R mutations (see Supplementary material online, FigureS1A–1C).

Relation of mitral valve parameters to age in FLNA-MVD

The main MV parameters correlated strongly to age in FLNA patients, especially in males, in agreement with a degenerative process of the MV apparatus (Figure 3). We further stratified FLNA-MVD adult patients in two groups under and above 40 years old. Although younger adults (≤40 years old) were taller, PL length [19.6 (confidence interval (CI) 25–75%; 18.3–20.3) vs. 15.3 mm (13.8–16.5), P = 0.015] and tip thickness [5.3 (3.9–5.4) vs. 3.1 mm (2.9–3.2), P = 0.032] were greater in older FLNA mutated men. Mitral valve lesions were detected in childhood especially in males (at 2 months in the younger one), clearly suggesting that valves lesions are also developmental lesions. Indeed fetal echocardiography carried out in two of them diagnosed MVD before birth.

Figure 3
Relation of age to (A) anterior and posterior leaflets length, (B) mitral annulus diameter, and (C and D) leaflets thickness in patients of both genders, with (black squares or circles) or without (white squares or circles) FLNA mutations. Values of all MV parameters increase with age up to 16–20 years old and were eventually quite stable in controls. All parameters have greater values in FLNA-MVD patients at any adult age, with a divergence between the regression slope in FLNA-MVD patients and controls. AL, anterior leaflet; PL, posterior leaflet.
View largeDownload slide

Relation of age to (A) anterior and posterior leaflets length, (B) mitral annulus diameter, and (C and D) leaflets thickness in patients of both genders, with (black squares or circles) or without (white squares or circles) FLNA mutations. Values of all MV parameters increase with age up to 16–20 years old and were eventually quite stable in controls. All parameters have greater values in FLNA-MVD patients at any adult age, with a divergence between the regression slope in FLNA-MVD patients and controls. AL, anterior leaflet; PL, posterior leaflet.

Figure 3
Relation of age to (A) anterior and posterior leaflets length, (B) mitral annulus diameter, and (C and D) leaflets thickness in patients of both genders, with (black squares or circles) or without (white squares or circles) FLNA mutations. Values of all MV parameters increase with age up to 16–20 years old and were eventually quite stable in controls. All parameters have greater values in FLNA-MVD patients at any adult age, with a divergence between the regression slope in FLNA-MVD patients and controls. AL, anterior leaflet; PL, posterior leaflet.
View largeDownload slide

Relation of age to (A) anterior and posterior leaflets length, (B) mitral annulus diameter, and (C and D) leaflets thickness in patients of both genders, with (black squares or circles) or without (white squares or circles) FLNA mutations. Values of all MV parameters increase with age up to 16–20 years old and were eventually quite stable in controls. All parameters have greater values in FLNA-MVD patients at any adult age, with a divergence between the regression slope in FLNA-MVD patients and controls. AL, anterior leaflet; PL, posterior leaflet.

Mitral regurgitation

Valve regurgitation (see Supplementary material online, TableS1) was assessed in all FLNA-MVD patients (n = 65). Mitral regurgitation was moderate or severe in 10 of 25 (40%) male patients and in 9 of 17 (53%) adult men, but in only 3 out of 40 (8%) female patients (P < 0.0001). Mechanism of MR was prolapse and/or annulus enlargement in male while the mechanism was either prolapse or pseudo-prolapse in female patients with a restrictive motion of the PL.

Aortic, tricuspid, and pulmonary valves

Polyvalvular disease (see supplementary material online, FigureS3), defined as the involvement of at least two valves, was found in 23 (35%) of 65 FLNA patients, mainly in male patients (n = 20, 80%). Aortic, tricuspid, and pulmonary involvement translated into moderate billowing or prolapse and led to severe regurgitation of the aortic valve only. Some patients had thickened aortic cusps with restricted motion. Bicuspid aortic valves were identified in 5 (7.7%) patients and 1 (1%) control (P = 0.07). All valve lesions appeared more severe in FLNA-H743P and G288R patients as compared with FLNA-P637Q, but the limited number of H743P or G288R patients precluded any reliable comparison. In FLNA-H743P and G288R patients polyvalvular involvement was frequent (50%), mainly in the form of moderate billowing.

Thoracic aorta

In adult patients, outflow tract diameter (12.2 ± 1.3 vs. 11.8 ± 1.0 mm/m2, P = 0.15) and ascending aorta size (15.3 ± 3.1 vs. 15.0 ± 2.4 mm/m2, P = 0.52) did not differ between FLNA patients and relatives but aortic sinus was slightly larger (17.3 ± 2.5 vs. 16.3 ± 1.9 mm/m2, P = 0.04). One FLNA patient died awaiting thoracic aorta aneurysm surgery, and another patient (75 year old) developed a 52 mm thoracic aorta dilatation, 24 years after bicuspid aortic valve surgery. Ascending aorta diameter was smaller than 35 mm in other FLNA patients but was found at 44 mm in one control relative.

Cardiac surgery and follow-up

Out of the 246 subjects (72 mutated), 14 patients underwent cardiac surgery. Cardiac surgery was performed in three control relatives and consisted in coronary artery bypass grafting (75-year-old man), myxoma resection (81-year-old woman), and MV replacement (69-year-old man). Cardiac surgery was performed in 11 out of 72 FLNA-MVD patients (9 men, 3–63 year old) and consisted in either mitral or aortic or both valves surgery. Mitral regurgitation was treated mainly by MV repair and annulus undersizing (replacement in one G288R patient).

Compared with controls (Figure 4), overall survival tended to decrease [80.6 ± 7.4 vs. 89.0 ± 5.2%, P = 0.13; (hazard ratio (HR) 2.0 (0.8–5.0), P = 0.15], owing to a decrease in male survival [55.9 ± 14.1 vs. 83.9 ± 8.8%, P = 0.011; HR 3.8 (1.3–11.3), P = 0.024]. Cardiac surgery rate was strongly increased in FLNA-MVD patients (33.3 ± 9.8 vs. 5.0 ± 4.9%, P < 0.0001) with a HR of 10.5 [95% CI (2.9–37.9), P < 0.0001], owing to a substantial lifetime increased risk of cardiac surgery (mainly valvular) in males [76.8 ± 14.1 vs. 9.1 ± 8.7%, P < 0.0001; HR 48 (6–385), P < 0.0001].

Figure 4
Life-time influence of FLNA-MVD (FLNA+) up to 70 years old on (A) overall survival, (B) survival in male patients, (C) overall cardiac surgery rate, and (D) cardiac surgery rate in male patients. The life-time risk of cardiac surgery depends essentially on the substantial increase in valve surgery in FLNA-MVD males.
View largeDownload slide

Life-time influence of FLNA-MVD (FLNA+) up to 70 years old on (A) overall survival, (B) survival in male patients, (C) overall cardiac surgery rate, and (D) cardiac surgery rate in male patients. The life-time risk of cardiac surgery depends essentially on the substantial increase in valve surgery in FLNA-MVD males.

Figure 4
Life-time influence of FLNA-MVD (FLNA+) up to 70 years old on (A) overall survival, (B) survival in male patients, (C) overall cardiac surgery rate, and (D) cardiac surgery rate in male patients. The life-time risk of cardiac surgery depends essentially on the substantial increase in valve surgery in FLNA-MVD males.
View largeDownload slide

Life-time influence of FLNA-MVD (FLNA+) up to 70 years old on (A) overall survival, (B) survival in male patients, (C) overall cardiac surgery rate, and (D) cardiac surgery rate in male patients. The life-time risk of cardiac surgery depends essentially on the substantial increase in valve surgery in FLNA-MVD males.

Discussion

The identification of FLNA as the first gene of non-syndromic MVD with an X-linked inheritance, in a large family and in additional small families, provided the unique opportunity to start deciphering phenotype variability of MV abnormalities. Hence, the present study aimed to depict the full spectrum of valve defects as well as the outcome of FLNA-MVD.

FLNA-MVD is a developmental and degenerative disease

Comprehensive echocardiography demonstrated unique organic features of FLNA-MVD that may change the paradigm of the so called ‘degenerative’ MV diseases. Indeed, FLNA-MVD is both a developmental and degenerative pathology. Valves lesions were diagnosed during childhood and even during fetal life highlighting the congenital origin of the disease, in agreement with experimental data in mice.19 On the other hand, MV lesions worsened in older patients of our series. This result is in line with the worsening of MV lesions over time in unselected patients with non-FLNA-MVP20 or with Marfan syndrome.21

Mitral valve prolapse and mitral regurgitation in Filamin-A patients

Consistent with an X-linked disease, FLNA mutations lead to a more severe phenotype in men, who are haemizygous for the mutation, as compared with women. In male patients, MV leaflet prolapse and annulus alterations are close to non-FLNA-MVP.1,22 However, no chordal rupture was diagnosed and chordae were rather shortened. Although MVP was found approximately in 70% of male and 40% of female patients, non-diagnostic or prodromal MV lesions were frequent, given a partial or complete penetrance in >65% of mutation carriers. In addition, subtle MV alterations were detected in almost all mutation carriers which highlight the large spectrum of MV abnormalities encountered in FLNA-MVD and likely in classical aetiologies of MVP.2 Mitral regurgitation was a frequent complication, especially in male patients, and was accessible to MV repair in most cases.

Subvalvular apparatus alteration

Discrete congenital sub-valvular lesions in FLNA-MVD patients are highly suggestive of a developmental disorder involving the whole MV apparatus. Chordae shortening is uncommon in MVP,22 but is in agreement with the initial publication of Monteleone and Fagan6 and with experimental data in mice.19 In addition, we also identified defects in the development of PM which appeared displaced towards the annulus, underdeveloped or even absent. Little is known regarding PM and chordae development. Whereas leaflets and chordae originate from atrio-ventricular cushions, PM arise from the ventricular wall. The delamination process separates PM from myocardial wall while primary leaflet tissue is progressively sculpted to form individualized chordae arising from PM tip.23 The absence of FLNA in the myocardium suggests that PM defects observed in FLNA-MVD are likely the consequence of an alteration of the complex and misunderstood interplay between myocardium and valve cushions.

Restrictive mitral valve motion in diastole

Surprisingly, FLNA mutations elicit both a MVP and a paradoxical restrictive motion in diastole. Such dual motion alteration is unusual in MVP disease; it has been reported in overt or sub-clinical rheumatic fever,24 in advanced stages of Barlow disease where some chordae can be thickened and retracted,5 and in severe MR with tethering of the non-prolapsed leaflet secondary to LV dilatation.25 The mechanism of the restrictive motion in FLNA-MVD is not clearly established but seems to be the consequence of mitral leaflets thickening and stiffening, PM displacement with shortness of primary chordae,19 and incomplete commissural opening. This paradoxical association is a unique feature in MVP. Hence, FLNA-MVD can be regarded as a unique cause of MVP beside Barlow disease and Fibro-elastic deficiency.

Polyvalvular involvement

Polyvalvular prolapse is a classical finding in connective tissue disorders such as Marfan syndrome21,26 and in some aneuploidy syndromes.27 By contrast, polyvalvular involvement is rare in euploid patients without extra-cardiac anomalies. The association of tricuspid valve prolapse to MVP is not very common.28 In a large series of 400 patients with MVP,29 only 11 (3%) had multiple valve involvement (tricuspid and aortic). Most of them were male as in FLNA-MVD. Polyvalvular involvement is a frequent finding in FLNA-MVD, especially in male patients, suggesting a defect in valvulogenesis.7,12,13 Indeed, during heart morphogenesis, FLNA is expressed in all valvular cushions19 and likely explains multiple valves lesions. Finally, although the difference with control relatives did not reach significance, bicuspid aortic valve is a relatively frequent finding and might be a developmental consequence of FLNA mutations.12 This hypothesis is reinforced by the frequent finding of bicuspid valves in FLNA-mice (data not shown).

Influence of Filamin-A mutation on outcome

It is noteworthy that FLNA-MVD is associated with a substantial life-time risk of cardiac valve surgery, up to 75% in male patients at 70 years old, which appears largely higher than in Barlow disease (estimated around 5–15%)21,22,30 highlighting the unusual severity of this MV disease and the need for early diagnosis and close monitoring.

Limitations

Although we gathered echocardiography and outcome data from four different families with three different mutations, most FLNA-MVD subjects were relatives linked to a common ancestor born in the 18th century (P637Q family). Echocardiography data were available in only 162 (66%) subjects but included 90% of known mutated patients. In this exploratory study, multiple statistical comparisons were carried out so that some marginally significant differences can be due to chance.

Conclusion

FLNA-MVD is a unique X-linked disease with both developmental and degenerative alterations, involving the whole MV apparatus and other valves. FLNA-MVD presents specific characteristics that differ from the usual forms of MVP ( Take home figure). Beside classical features of MVP, leaflet motion is paradoxically restricted in diastole. Diagnosis of FLNA-MVD should therefore be sought in male patients with unusual features of MVP and can be an alternative aetiology for explaining restrictive valve lesions. Non-diagnostic or prodromal forms of MV disease are frequent. FLNA-MVD is associated with a substantial life-time risk of valve surgery, but MR can be generally cured by classical repair.

Take home figure
(A) Aspect of mitral valve apparatus with the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in FLNA-MVD, (B) myxomatous change of a mitral leaflet (colloidal iron), (C) degenerative aspect of FLNA-MVD with progressive lengthening of leaflets (AL, anterior leaflet; PL, posterior leaflet), and (D) substantial life-time risk of cardiac surgery in FLNA-MVD males.
View largeDownload slide

(A) Aspect of mitral valve apparatus with the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in FLNA-MVD, (B) myxomatous change of a mitral leaflet (colloidal iron), (C) degenerative aspect of FLNA-MVD with progressive lengthening of leaflets (AL, anterior leaflet; PL, posterior leaflet), and (D) substantial life-time risk of cardiac surgery in FLNA-MVD males.

Take home figure
(A) Aspect of mitral valve apparatus with the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in FLNA-MVD, (B) myxomatous change of a mitral leaflet (colloidal iron), (C) degenerative aspect of FLNA-MVD with progressive lengthening of leaflets (AL, anterior leaflet; PL, posterior leaflet), and (D) substantial life-time risk of cardiac surgery in FLNA-MVD males.
View largeDownload slide

(A) Aspect of mitral valve apparatus with the paradoxical association of mitral valve prolapse (systole) and restrictive motion in diastole (doming, arrows) in FLNA-MVD, (B) myxomatous change of a mitral leaflet (colloidal iron), (C) degenerative aspect of FLNA-MVD with progressive lengthening of leaflets (AL, anterior leaflet; PL, posterior leaflet), and (D) substantial life-time risk of cardiac surgery in FLNA-MVD males.

The present study is the first to start deciphering the genotype–phenotype relationships in FLNA-MVD. Thanks to an international collaboration on FLNA-MVD we were able to characterize precisely the disease. Our work paves the way for further gene discovery and phenotype–genotype assessment in either MVP or MVD which appear more various than previously thought. Familial screening and individualized management adapted to phenotype and predicted outcome according to causal gene should reduce complications of either MVP or MVD in the future.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgements

We are indebted to Monique Dupas, Marie Marrec, and Guenola Coste (Institut du Thorax, Nantes, France) for their assistance in patient enrolment and familial screening, and to Aurélie Thollet for her assistance in MVP research organization.

Funding

Leducq Foundation Transatlantic Network of Excellence in Mitral Valve Disease (2008-2013, Paris, France); Fondation GenaVie (2010, Nantes, France); Fédération Française de Cardiologie (2011, Paris, France); French Ministry of Health ‘PHRC National 2007’ (n°20-17); and ‘PHRC-I 2012’ (API12/N/019, Paris, France). NIH: HL131546 (RAN), GM103444 (RAN), and HL127692 (RAN, DM, SS), K23HL116652 (FD), HL109506 (RAL, EA), HL128099 (RAL). Inserm Translational Research Grant (2012-2016, Paris, France) to T.L.T.

Conflict of interest: none declared.

References

1
Levine
RA
,
Hagége
AA
,
Judge
DP
,
Padala
M
,
Dal-Bianco
JP
,
Aikawa
E
,
Beaudoin
J
,
Bischoff
J
,
Bouatia-Naji
N
,
Bruneval
P
,
Butcher
JT
,
Carpentier
A
,
Chaput
M
,
Chester
AH
,
Clusel
C
,
Delling
FN
,
Dietz
HC
,
Dina
C
,
Durst
R
,
Fernandez-Friera
L
,
Handschumacher
MD
,
Jensen
MO
,
Jeunemaitre
XP
,
Le Marec
H
,
Le Tourneau
T
,
Markwald
RR
,
Mérot
J
,
Messas
E
,
Milan
DP
,
Neri
T
,
Norris
RA
,
Peal
D
,
Perrocheau
M
,
Probst
V
,
Pucéat
M
,
Rosenthal
N
,
Solis
J
,
Schott
J-J
,
Schwammenthal
E
,
Slaugenhaupt
SA
,
Song
J-K
,
Yacoub
MH.
Mitral valve disease–morphology and mechanisms
.
Nat Rev Cardiol
 
2015
;
12
:
689
–
710
.
Google Scholar
Crossref
Search ADS
PubMed
 
2
Nesta
F
,
Leyne
M
,
Yosefy
C
,
Simpson
C
,
Dai
D
,
Marshall
JE
,
Hung
J
,
Slaugenhaupt
SA
,
Levine
RA.
New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies
.
Circulation
 
2005
;
112
:
2022
–
2030
.
Google Scholar
Crossref
Search ADS
PubMed
 
3
Fornes
P
,
Heudes
D
,
Fuzellier
JF
,
Tixier
D
,
Bruneval
P
,
Carpentier
A.
Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: a histomorphometric study of 130 excised segments
.
Cardiovasc Pathol
 
1999
;
8
:
81
–
92
.
Google Scholar
Crossref
Search ADS
PubMed
 
4
Adams
DH
,
Rosenhek
R
,
Falk
V.
Degenerative mitral valve regurgitation: best practice revolution
.
Eur Heart J
 
2010
;
31
:
1958
–
1966
.
Google Scholar
Crossref
Search ADS
PubMed
 
5
Anyanwu
AC
,
Adams
DH.
Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency
.
Semin Thorac Cardiovasc Surg
 
2007
;
19
:
90
–
96
.
Google Scholar
Crossref
Search ADS
PubMed
 
6
Monteleone
PL
,
Fagan
LF.
Possible X-linked congenital heart disease
.
Circulation
 
1969
;
39
:
611
–
614
.
Google Scholar
Crossref
Search ADS
PubMed
 
7
Kyndt
F
,
Gueffet
JP
,
Probst
V
,
Jaafar
P
,
Legendre
A
,
Le Bouffant
F
,
Toquet
C
,
Roy
E
,
McGregor
L
,
Lynch
SA
,
Newbury-Ecob
R
,
Tran
V
,
Young
I
,
Trochu
JN
,
Le Marec
H
,
Schott
JJ.
Mutations in the gene encoding Filamin A as a cause for familial cardiac valvular dystrophy
.
Circulation
 
2007
;
115
:
40
–
49
.
Google Scholar
Crossref
Search ADS
PubMed
 
8
Freed
LA
,
Acierno
JS
Jr
,
Dai
D
,
Leyne
M
,
Marshall
JE
,
Nesta
F
,
Levine
RA
,
Slaugenhaupt
SA.
A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4
.
Am J Hum Genet
 
2003
;
72
:
1551
–
1559
.
Google Scholar
Crossref
Search ADS
PubMed
 
9
Kyndt
F
,
Schott
J-J
,
Trochu
J-N
,
Baranger
F
,
Herbert
O
,
Scott
V
,
Fressinaud
E
,
David
A
,
Moisan
J-P
,
Bouhour
J-B
,
Le Marec
H
,
Bénichou
B.
Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28
.
Am J Hum Genet
 
1998
;
62
:
627
–
632
.
Google Scholar
Crossref
Search ADS
PubMed
 
10
Durst
R
,
Sauls
K
,
Peal
DS
,
deVlaming
A
,
Toomer
K
,
Leyne
M
,
Salani
M
,
Talkowski
ME
,
Brand
H
,
Perrocheau
M
,
Simpson
C
,
Jett
C
,
Stone
MR
,
Charles
F
,
Chiang
C
,
Lynch
SN
,
Bouatia-Naji
N
,
Delling
FN
,
Freed
LA
,
Tribouilloy
C
,
Le Tourneau
T
,
LeMarec
H
,
Fernandez-Friera
L
,
Solis
J
,
Trujillano
D
,
Ossowski
S
,
Estivill
X
,
Dina
C
,
Bruneval
P
,
Chester
A
,
Schott
JJ
,
Irvine
KD
,
Mao
Y
,
Wessels
A
,
Motiwala
T
,
Puceat
M
,
Tsukasaki
Y
,
Menick
DR
,
Kasiganesan
H
,
Nie
X
,
Broome
AM
,
Williams
K
,
Johnson
A
,
Markwald
RR
,
Jeunemaitre
X
,
Hagege
A
,
Levine
RA
,
Milan
DJ
,
Norris
RA
,
Slaugenhaupt
SA.
Mutations in DCHS1 cause mitral valve prolapse
.
Nature
 
2015
;
525
:
109
–
113
.
Google Scholar
Crossref
Search ADS
PubMed
 
11
Dina
C
,
Bouatia-Naji
N
,
Tucker
N
,
Delling
FN
,
Toomer
K
,
Durst
R
,
Perrocheau
M
,
Fernandez-Friera
L
,
Solis
J
,
Le Tourneau
T
,
Chen
MH
,
Probst
V
,
Bosse
Y
,
Pibarot
P
,
Zelenika
D
,
Lathrop
M
,
Hercberg
S
,
Roussel
R
,
Benjamin
EJ
,
Bonnet
F
,
Lo
SH
,
Dolmatova
E
,
Simonet
F
,
Lecointe
S
,
Kyndt
F
,
Redon
R
,
Le Marec
H
,
Froguel
P
,
Ellinor
PT
,
Vasan
RS
,
Bruneval
P
,
Markwald
RR
,
Norris
RA
,
Milan
DJ
,
Slaugenhaupt
SA
,
Levine
RA
,
Schott
JJ
,
Hagege
AA
,
Jeunemaitre
X.
Genetic association analyses highlight biological pathways underlying mitral valve prolapse
.
Nat Genet
 
2015
;
47
:
1206
–
1211
.
Google Scholar
Crossref
Search ADS
PubMed
 
12
Bernstein
JA
,
Bernstein
D
,
Hehr
U
,
Hudgins
L.
Familial cardiac valvulopathy due to Filamin A mutation
.
Am J Med Genet A
 
2011
;
155A
:
2236
–
2241
.
Google Scholar
Crossref
Search ADS
PubMed
 
13
Aalberts
JJJ
,
van Tintelen
JP
,
Oomen
T
,
Bergman
JE
,
Halley
DJ
,
Jongbloed
JD
,
Suurmeijer
AJ
,
van den Berg
MP.
Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse
.
Am J Med Genet A
 
2014
;
164
:
113
–
119
.
Google Scholar
Crossref
Search ADS
 
14
Duval
D
,
Lardeux
A
,
Le Tourneau
T
,
Norris
RA
,
Markwald
RR
,
Sauzeau
V
,
Probst
V
,
Le Marec
H
,
Levine
R
,
Schott
JJ
,
Merot
J.
Valvular dystrophy associated Filamin A mutations reveal a new role of its first repeats in small-gtpase regulation
.
Biochim Biophys Acta
 
2014
;
1843
:
234
–
244
.
Google Scholar
Crossref
Search ADS
PubMed
 
15
Trochu
JN
,
Kyndt
F
,
Schott
JJ
,
Gueffet
JP
,
Probst
V
,
Benichou
B
,
Le Marec
H.
Clinical characteristics of a familial inherited myxomatous valvular dystrophy mapped to Xq28
.
J Am Coll Cardiol
 
2000
;
35
:
1890
–
1897
.
Google Scholar
Crossref
Search ADS
PubMed
 
16
Lancellotti
P
,
Moura
L
,
Pierard
LA
,
Agricola
E
,
Popescu
BA
,
Tribouilloy
C
,
Hagendorff
A
,
Monin
JL
,
Badano
L
,
Zamorano
JL
,
Sicari
R
,
Vahanian
A
,
Roelandt
JRTC.
European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)
.
Eur J Echocardiogr
 
2010
;
11
:
307
–
332
.
Google Scholar
Crossref
Search ADS
PubMed
 
17
Lang
RM
,
Badano
LP
,
Mor-Avi
V
,
Afilalo
J
,
Armstrong
A
,
Ernande
L
,
Flachskampf
FA
,
Foster
E
,
Goldstein
SA
,
Kuznetsova
T
,
Lancellotti
P
,
Muraru
D
,
Picard
MH
,
Rietzschel
ER
,
Rudski
L
,
Spencer
KT
,
Tsang
W
,
Voigt
JU.
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
J Am Soc Echocardiogr
 
2015
;
28
:
1
–
39.e14
.
Google Scholar
Crossref
Search ADS
PubMed
 
18
Vahanian
A
,
Alfieri
O
,
Andreotti
F
,
Antunes
MJ
,
Baron-Esquivias
G
,
Baumgartner
H
,
Borger
MA
,
Carrel
TP
,
De Bonis
M
,
Evangelista
A
,
Falk
V
,
Iung
B
,
Lancellotti
P
,
Pierard
L
,
Price
S
,
Schafers
HJ
,
Schuler
G
,
Stepinska
J
,
Swedberg
K
,
Takkenberg
J
,
Von Oppell
UO
,
Windecker
S
,
Zamorano
JL
,
Zembala
M
,
Bax
JJ
,
Baumgartner
H
,
Ceconi
C
,
Dean
V
,
Deaton
C
,
Fagard
R
,
Funck-Brentano
C
,
Hasdai
D
,
Hoes
A
,
Kirchhof
P
,
Knuuti
J
,
Kolh
P
,
McDonagh
T
,
Moulin
C
,
Popescu
BA
,
Reiner
Z
,
Sechtem
U
,
Sirnes
PA
,
Tendera
M
,
Torbicki
A
,
Vahanian
A
,
Windecker
S
,
Popescu
BA
,
Von Segesser
L
,
Badano
LP
,
Bunc
M
,
Claeys
MJ
,
Drinkovic
N
,
Filippatos
G
,
Habib
G
,
Kappetein
AP
,
Kassab
R
,
Lip
GY
,
Moat
N
,
Nickenig
G
,
Otto
CM
,
Pepper
J
,
Piazza
N
,
Pieper
PG
,
Rosenhek
R
,
Shuka
N
,
Schwammenthal
E
,
Schwitter
J
,
Mas
PT
,
Trindade
PT
,
Walther
T.
Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
.
Eur Heart J
 
2012
;
33
:
2451
–
2496
.
Google Scholar
Crossref
Search ADS
PubMed
 
19
Sauls
K
,
de Vlaming
A
,
Harris
BS
,
Williams
K
,
Wessels
A
,
Levine
RA
,
Slaugenhaupt
SA
,
Goodwin
RL
,
Pavone
LM
,
Merot
J
,
Schott
JJ
,
Le Tourneau
T
,
Dix
T
,
Jesinkey
S
,
Feng
Y
,
Walsh
C
,
Zhou
B
,
Baldwin
S
,
Markwald
RR
,
Norris
RA.
Developmental basis for Filamin-A-associated myxomatous mitral valve disease
.
Cardiovasc Res
 
2012
;
96
:
109
–
119
.
Google Scholar
Crossref
Search ADS
PubMed
 
20
Avierinos
JF
,
Detaint
D
,
Messika-Zeitoun
D
,
Mohty
D
,
Enriquez-Sarano
M.
Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community
.
Am J Cardiol
 
2008
;
101
:
662
–
667
.
Google Scholar
Crossref
Search ADS
PubMed
 
21
Détaint
D
,
Faivre
L
,
Collod-Beroud
G
,
Child
AH
,
Loeys
BL
,
Binquet
C
,
Gautier
E
,
Arbustini
E
,
Mayer
K
,
Arslan-Kirchner
M
,
Stheneur
C
,
Halliday
D
,
Beroud
C
,
Bonithon-Kopp
C
,
Claustres
M
,
Plauchu
H
,
Robinson
PN
,
Kiotsekoglou
A
,
De Backer
J
,
Adès
L
,
Francke
U
,
De Paepe
A
,
Boileau
C
,
Jondeau
G.
Cardiovascular manifestations in men and women carrying a fbn1 mutation
.
Eur Heart J
 
2010
;
31
:
2223
–
2229
.
Google Scholar
Crossref
Search ADS
PubMed
 
22
Freed
LA
,
Benjamin
EJ
,
Levy
D
,
Larson
MG
,
Evans
JC
,
Fuller
DL
,
Lehman
B
,
Levine
RA.
Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the framingham heart study
.
J Am Coll Cardiol
 
2002
;
40
:
1298
–
1304
.
Google Scholar
Crossref
Search ADS
PubMed
 
23
Victor
S
,
Nayak
VM.
Variations in the papillary muscles of the normal mitral valve and their surgical relevance
.
J Card Surg
 
1995
;
10
:
597
–
607
.
Google Scholar
Crossref
Search ADS
PubMed
 
24
Tomaru
T
,
Uchida
Y
,
Mohri
N
,
Mori
W
,
Furuse
A
,
Asano
K.
Postinflammatory mitral and aortic valve prolapse: a clinical and pathological study
.
Circulation
 
1987
;
76
:
68
–
76
.
Google Scholar
Crossref
Search ADS
PubMed
 
25
Otani
K
,
Takeuchi
M
,
Kaku
K
,
Haruki
N
,
Yoshitani
H
,
Eto
M
,
Tamura
M
,
Okazaki
M
,
Abe
H
,
Fujino
Y
,
Nishimura
Y
,
Levine
RA
,
Otsuji
Y.
Evidence of a vicious cycle in mitral regurgitation with prolapse: secondary tethering attributed to primary prolapse demonstrated by three-dimensional echocardiography exacerbates regurgitation
.
Circulation
 
2012
;
126
:
S214
–
S221
.
Google Scholar
Crossref
Search ADS
PubMed
 
26
Edouard
T
,
Prost-Squarcioni
C
,
Dulac
Y
,
Vaysse
F
,
Cave
H
,
Saugier-Veber
P
,
Bourrouillou
G
,
Verloes
A
,
Tauber
M
,
Bieth
E.
Polyvalvular heart disease with joint hypermobility, characteristic facies, and particular skin abnormalities: new cases of ‘polyvalvular heart disease syndrome’ or new association?
Eur J Med Genet
 
2010
;
53
:
29
–
34
.
Google Scholar
Crossref
Search ADS
PubMed
 
27
Van Praagh
S
,
Truman
T
,
Firpo
A
,
Bano-Rodrigo
A
,
Fried
R
,
McManus
B
,
Engle
MA
,
Van Praagh
R.
Cardiac malformations in trisomy-18: a study of 41 postmortem cases
.
J Am Coll Cardiol
 
1989
;
13
:
1586
–
1597
.
Google Scholar
Crossref
Search ADS
PubMed
 
28
Emine
BS
,
Murat
A
,
Mehmet
B
,
Mustafa
K
,
Gokturk
I.
Flail mitral and tricuspid valves due to myxomatous disease
.
Eur J Echocardiogr
 
2008
;
9
:
304
–
305
.
Google Scholar
PubMed
 
29
Rippe
J
,
Angoff
G
,
Sloss
L
,
Wynne
J
,
Alpert
J.
Multiple floppy valves: an echocardiographic syndrome
.
Am J Med
 
1979
;
66
:
817
–
824
.
Google Scholar
Crossref
Search ADS
PubMed
 
30
Wilcken
D
,
Hickey
A.
Lifetime risk for patients with mitral valve prolapse of developing severe valve regurgitation requiring surgery
.
Circulation
 
1988
;
78
:
10
–
14
.
Google Scholar
Crossref
Search ADS
PubMed
 
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)
Topic:
Issue Section:
Valvular heart disease
Download all figures
  • Supplementary data

    • Supplementary data

    Supplementary Figure 1
     - png file
    Supplementary Figure 2
     - png file
    Supplementary Figure 3
     - png file
    Supplementary Tables
     - doc file
    Supplementary Data
     - doc file

    Comments

    0 Comments
    Comments (0)
    Submit a comment
    You have entered an invalid code
    Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.